CH.00 / OPENING BILLBOARD
an indexed dossier on bremelanotide
PT-141 is the only melanocortin agonist the United States has ever approved for sexual desire. Its record reads like a season of episodes: a rat study in 2004, a male-intranasal detour, two pivotal female trials, and a 2024 sequel now in progress. This is the dossier.
The short version
PT-141 (bremelanotide) is a lab-made cyclic peptide that acts on receptors in the brain — not on blood vessels — to switch on the desire and motivation side of sexual response. One specific form of it, the prescription product, was approved by the FDA in June 2019 for a narrow use: premenopausal women with acquired low sexual desire (HSDD) that causes them real distress. That is the entire approved indication. Every other use — in men, in postmenopausal women, for erectile function or performance — is off-label or investigational. A separate unregulated powder sold as a research chemical under the same name carries no pharmaceutical oversight of identity, purity, or concentration. What follows in this dossier is the peer-reviewed record of what the trials measured, what the label says, and what the open questions are — with every quantitative claim tied to a primary source. See the effects page for a plain account of what people report and the honest tolerability cost.
The compound, in one card
Bremelanotide is a synthetic cyclic heptapeptide — seven amino acids closed into a ring through a lactam bridge between aspartate and lysine side chains. It carries the conserved His-D-Phe-Arg-Trp pharmacophore of alpha-melanocyte-stimulating hormone, and that single structural inheritance is the reason every chapter that follows happens at all [1].
It is the C-terminal-deamidated active metabolite of an earlier compound, melanotan II, re-engineered for receptor selectivity and proteolytic stability. The cyclization restricts the molecule's conformation; the D-phenylalanine substitution shifts its receptor preference away from skin pigmentation and toward the central nervous system [1]. CAS 189691-06-3. Molecular weight 1,025.18 daltons. Approved by the U.S. Food and Drug Administration on 21 June 2019.
That approval covers exactly one indication: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not better explained by another medical condition, medication, or relationship issue [1]. Nothing wider. The label is narrow on purpose.
Why the central mechanism matters
Most pharmacology aimed at sexual function has worked from the outside in — the genital vasculature, the smooth muscle, the peripheral cGMP cascade. Bremelanotide does not. It binds melanocortin receptors in the hypothalamus, principally MC4R in the paraventricular nucleus and medial preoptic area, and the rest of the effect cascades downstream from those neurons [2][3].
Downstream means dopamine release in the mesolimbic reward circuit. It means oxytocin release from magnocellular PVN neurons. It means engagement of the medial preoptic area, which is the final common pathway for what behavioral neuroscientists call proceptive sexual behavior — the appetitive, partner-seeking, motivational phase that precedes the consummatory one [2][3].
The Pfaus 2004 rat study is where this became visible at the behavioral level. At 100 to 200 micrograms per kilogram subcutaneously, female Long-Evans rats showed selectively increased solicitations — the hops, darts, and ear-wiggles that signal partner-seeking — without changes in lordosis, pacing, or measures of sexual reward [3]. The drug was facilitating desire, not performance. That single result is what launched the human program.
The Phase 3 record
The pivotal evidence sits in two trials known together as RECONNECT, pooled and reported in Obstetrics & Gynecology in 2019 [4]. Across 1,247 randomized premenopausal women with acquired, generalized HSDD, subcutaneous bremelanotide at 1.75 mg on demand produced statistically significant improvements over placebo on both co-primary endpoints — the Female Sexual Function Index Desire domain (FSFI-D) and item 13 of the Female Sexual Distress Scale (FSDS-DAO-13) — across 24 weeks [4].
The effect size was modest. FSFI-D change of +0.35 versus +0.21. FSDS-DAO-13 change of −0.74 versus −0.42. Both p<0.001. A 52-week open-label extension carried the safety record forward without new signals [5], and a 2022 integrated subgroup analysis found the effect held across age, BMI, hormonal contraceptive use, and HSDD duration subgroups [6]. Whether the statistical signal mapped to meaningful patient-level benefit became the central debate around the 2019 approval. The dossier presents both sides on /research.
What this site is
PT-141 MD is an independent editorial project. It is not a clinic, it does not employ clinicians, and it is not affiliated with the manufacturer, the original developer, or any current licensee of the approved product. It does not sell anything.
What it does is publish a curated dossier on bremelanotide built entirely from the peer-reviewed literature, the FDA approval documents, and the active clinical-trial registry [7]. Every quantitative claim on every page cites a primary source. The reference list runs at the back. Hover any bracketed citation for the metadata.
The pages are organized as chapters. Open the one that's relevant — mechanism on /research, labeled dosing and pharmacokinetics on /dosage, common questions and the controversies on /faq, full citation list on /references — or read the whole season.